Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 10:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 904 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Use of a Tablet Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

Remote Monitoring of Respiratory Health

NCT04739943
View directory record Official record
Conditions
Chronic Respiratory Disease, Asthma, Copd
Interventions
Mobile Monitoring
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
1 Month and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 6, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

NCT02651584
View directory record Official record
Conditions
Opioid Use Disorders
Interventions
CAM2038 SC injection, SL BPN/NX tabs, placebo SC injections, SL placebo tablets
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
36
States / cities
Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Sep 6, 2026, 10:03 AM EDT
Completed Not applicable Interventional

GYNecologic Cancer-Related COGnitive Impairment

NCT06662435
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Cervical Cancers, Vulvar Cancers, Uterine Cancer, Cervix Cancer, Ovary Cancer
Interventions
GYNCOG
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 6, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

NCT01713946
View directory record Official record
Conditions
Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions
RAD001, Placebo, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 6, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy

NCT01041859
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Tapentadol extended release (ER), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
60
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2013 · Synced Sep 6, 2026, 10:03 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2

NCT05040659
View directory record Official record
Conditions
Anosmia, Asymptomatic COVID-19, COVID-19 Respiratory Infection, Influenza, Healthy, PASC Post Acute Sequelae of COVID 19
Interventions
AROMHA Longitudinal Smell Test
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 6, 2026, 10:03 AM EDT
Completed Not applicable Interventional Results available

Pragmatic Comparative Effectiveness Trial of Evidence-based, On-demand, Digital Behavioral Treatments for Chronic Pain

NCT04933474
View directory record Official record
Conditions
Chronic Pain
Interventions
painTRAINER®, Skills-Based VR
Behavioral · Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
13 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 6, 2026, 10:03 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of an Oral Probiotic Tablet on Oral Bacteria and Clinical Measurements (ProBiora3)

NCT01520974
View directory record Official record
Conditions
Oral Health
Interventions
ProBiora3 mints, Placebo tablet
Other
Lead sponsor
Oragenics, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Sep 6, 2026, 10:03 AM EDT
Enrolling by invitation Not applicable Interventional

Pre-Pilot (R61) WINGS+++: mHealth to Improve MOUD Uptake in Women Experiencing Intimate Partner Violence and PTSD

NCT07665502
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders, Intimate Partner Violence (IPV), Stress Disorders, Post-Traumatic, Domestic Violence, Medication for Opioid Use Disorder (MOUD), Post Traumatic Stress Disorder PTSD
Interventions
Pre-Pilot WINGS++++
Behavioral
Lead sponsor
Dawn A. Goddard-Eckrich
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
New York, New York • Newburgh, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 6, 2026, 10:03 AM EDT
Completed Early Phase 1 Interventional

N-of-1 Trials for Blood Pressure Medications in Adults

NCT02744456
View directory record Official record
Conditions
Hypertension, High Blood Pressure
Interventions
Losartan, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 6, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers

NCT01454622
View directory record Official record
Conditions
Healthy
Interventions
A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 5, 2013 · Synced Sep 6, 2026, 10:03 AM EDT
Terminated Not applicable Interventional Results available

Telemonitoring After Surgery to Preserve Limb Function in Optimizing Mobility in Cancer Survivors With Skeletal Metastases

NCT02715856
View directory record Official record
Conditions
Bone Metastases, Cancer Survivor, Metastatic Malignant Neoplasm in the Bone
Interventions
Monitoring Device, Physical Activity Measurement, Quality-of-Life Assessment, Questionnaire Administration, Standard Follow-Up Care, Survey Administration
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Sep 6, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma

NCT02483975
View directory record Official record
Conditions
Asthma
Interventions
FF, Placebo, Montelukast, Albuterol/Salbutamol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Little Rock, Arkansas • Alhambra, California • Costa Mesa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 6, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)

NCT03608241
View directory record Official record
Conditions
Healthy Females
Interventions
PF-06651600, Ethinyl estradiol (EE) and levonogestrel (LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 6, 2026, 10:03 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Primary Connections for Youth and Families

NCT05964010
View directory record Official record
Conditions
Substance Use
Interventions
Standard Screening, Standard Psychoeducation, Standard Brief Negotiated Interview (BNI), Standard Referral to Treatment (RT), Family Screening, Family Psychoeducation, Family Brief Negotiated Interview (BNI), Family Facilitated Conversation (FC) & Referral to Treatment (RT)
Behavioral
Lead sponsor
The National Center on Addiction and Substance Abuse at Columbia University
Other
Eligibility
12 Years to 17 Years
Enrollment
2,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 6, 2026, 10:03 AM EDT
Completed Not applicable Interventional Results available

Effect of Ibuprofen on Postoperative Opiate Medication Use and Shoulder Functional Outcomes

NCT02588027
View directory record Official record
Conditions
Rotator Cuff Tear Arthropathy
Interventions
Ibuprofen, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 6, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NCT01391962
View directory record Official record
Conditions
Sarcoma, Alveolar Soft Part
Interventions
Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 6, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Learn How Well a Single Dose of the Study Treatment Naproxen Sodium and Caffeine Combined in One Tablet (Fixed-dose Combination) Works to Relieve Pain After Dental Surgeries Compared to the Single Ingredients and to Placebo

NCT05485805
View directory record Official record
Conditions
Postoperative Dental Pain
Interventions
Naproxen sodium and caffeine (BAY2880376), Naproxen sodium (Aleve), Caffeine, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years and older
Enrollment
541 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 6, 2026, 10:03 AM EDT
Completed Phase 2 Interventional Results available

Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)

NCT03457701
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe), Ferrous sulfate containing the stable iron isotope (58Fe)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Fort Worth, Texas • Lufkin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 6, 2026, 10:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 6, 2026, 10:03 AM EDT
Terminated Phase 2 Interventional Results available

HLAB-002 of ANS-6637 for Alcohol Use Disorder

NCT03970109
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
ANS-6637, Placebo oral tablet
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
New Haven, Connecticut • Providence, Rhode Island • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 6, 2026, 10:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC)

NCT05064332
View directory record Official record
Conditions
Healthy
Interventions
PF-06650833, Ethinyl estradiol (EE) and levonogestrel (LN)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Sep 6, 2026, 10:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Southwest Hub for American Indian Youth Suicide Prevention Research

NCT03543865
View directory record Official record
Conditions
Suicide, Surveillance, Mental Health, Substance Use, Depressive Symptoms
Interventions
New Hope (NH), Elders Resilience (ER), Case Management (CM)
Behavioral · Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
16 Years to 29 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Whiteriver, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 6, 2026, 10:03 AM EDT
Recruiting Not applicable Interventional

Cognitive Behavioral Theory-assisted Virtual Reality for Chronic CANcer Pain (VR-CAN)

NCT07318519
View directory record Official record
Conditions
Cancer, Cancer Pain, Chronic Cancer Pain
Interventions
VR-CAN prototype chronic cancer pain therapy -- virtual reality program delivering CBT for chronic cancer pain management, Active Control -- two-dimensional tablet-delivered intervention
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 6, 2026, 10:03 AM EDT